Clinical Trials Sponsored by Osiris Therapeutics

Total 6382 results

Lykos Therapeutics

Withdrawn

Study of Safety and Effects of MDMA-assisted Therapy for Treatment of PTSD (NUMCAP1)

Posttraumatic Stress Disorder
Lykos Therapeutics

Completed

Exploring Mechanisms of Action in MDMA-assisted Psychotherapy for PTSD

Posttraumatic Stress Disorder

United States
Lykos Therapeutics

Completed

Psychological Effects of Methylenedioxymethamphetamine (MDMA) When Administered to Healthy Volunteers (MT-1)

Psychological Effects of Study Drug

United States
Spark Therapeutics

Active, not recruiting

A Patient Registry Study for Patients Treated With Voretigene Neparvovec in US

Confirmed Biallelic RPE65 Mutation-associated Retinal Dystrophy

United States
CytomX Therapeutics

Completed

PROCLAIM-CX-2029: A Trial to Find Safe and Active Doses of an Investigational Drug CX-2029 for Patients With Solid Tumors or DLBCL

Head and Neck Cancer | Esophageal Cancer | Non Small Cell Lung Cancer | Diffuse Large B Cell Lymphoma | Solid Tumor, Adult

United States, Spain, Korea, Republic of, United Kingdom
Spark Therapeutics

Active, not recruiting

Long-Term Safety and Efficacy of Spark-Sponsored Gene Therapies in Males With Hemophilia A

Hemophilia A

United States, Canada, Australia
RANI Therapeutics

Completed

Study Evaluating PK of Ustekinumab Administered Orally Via RaniPill™ Capsule

Healthy Volunteers

Australia
PTC Therapeutics

Completed

A Study of PTC923 in Participants With Phenylketonuria

Phenylketonuria

Spain, United States, Australia, Germany, United Kingdom, Brazil, Denmark, Canada, France, Georgia, Italy, Mexico, Netherlands, Portugal, Turkey
Spark Therapeutics

Completed

A Gene Transfer Study for Hemophilia A

Hemophilia A

United States, Australia, Canada, Israel, Thailand
CytomX Therapeutics

Terminated

PROCLAIM-CX-2009: A Trial to Find Safe and Active Doses of an Investigational Drug CX-2009 for Patients With Selected Solid Tumors

Breast Cancer | Head and Neck Cancer | Ovarian Cancer | Non Small Cell Lung Cancer | Solid Tumor, Adult

United States, Spain, Netherlands, United Kingdom
United Therapeutics

Completed

TRUST-2: Safety and Efficacy of Intravenous Remodulin® in Patients in India With Pulmonary Arterial Hypertension (PAH) (TRUST-2)

Pulmonary Arterial Hypertension
Intellia Therapeutics

Terminated

Study Investigating NTLA-5001 in Subjects With Acute Myeloid Leukemia

Acute Myeloid Leukemia

United States, United Kingdom
United Therapeutics

Completed

Addition of UT-15C SR to Pulmonary Arterial Hypertension Patients Currently Receiving Tyvaso®

Pulmonary Arterial Hypertension

United States
Akebia Therapeutics

Completed

Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera®) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects

Anemia Associated With Chronic Kidney Disease (CKD)

United States
Karuna Therapeutics

Completed

A Study to Assess Efficacy and Safety of KarXT in Acutely Psychotic Hospitalized Adult Patients With Schizophrenia (EMERGENT-2)

Schizophrenia | Schizophrenia; Psychosis

United States
PTC Therapeutics

Completed

Long-Term Safety and Efficacy Evaluation of EPI-743 in Children With Leigh Syndrome

Leigh Syndrome

United States
Corcept Therapeutics

Terminated

Study of Relacorilant in Combination With Nab-Paclitaxel in Patients With Metastatic Pancreatic Ductal Adenocarcinoma (RELIANT)

Metastatic Pancreatic Ductal Adenocarcinoma

United States
Myeloid Therapeutics

Suspended

A Study of MT-101 in Subjects With CD5+ Relapsed/Refractory TCL (IMAGINE)

Lymphoma, T-Cell, Cutaneous | Mycosis Fungoides | Lymphoma, T-Cell, Peripheral | Cell Therapy | Adoptive Cellular Immunotherapy

United States
Fate Therapeutics

Terminated

FT596 as a Monotherapy and in Combination With Anti-CD20 Monoclonal Antibodies

Lymphoma, B-Cell | Chronic Lymphocytic Leukemia

United States
Heron Therapeutics

Active, not recruiting

A Multi-surgery Assessment of ZYNRELEF (HTX-011), AMAZE. Master Protocol HTX-011-401.

Analgesia

United States
Corcept Therapeutics

Completed

A Study to Evaluate the Pharmacokinetics of the Current Capsule Formulation of CORT125134 in Healthy Subjects

Healthy

United States
Corcept Therapeutics

Completed

A Study to Evaluate the Effect of Food on the Oral Bioavailability of Relacorilant in Healthy Subjects

Healthy

United States
Tisento Therapeutics

Terminated

A Study of the Effects of CY6463 in Participants With Alzheimer's Disease With Vascular Pathology

Alzheimer's Disease With Vascular Pathology

United States
Akebia Therapeutics

Suspended

Study to Evaluate the Safety and Efficacy of Oral Vadadustat in Pediatric Participants With Anemia of Chronic Kidney Disease Naive to Erythropoiesis-Stimulating Agents (CORRECTION)

Anemia of Chronic Kidney Disease

United States
Harpoon Therapeutics

Active, not recruiting

A Phase 1 Open-label, Multicenter, Dose Escalation Study of the Safety, Tolerability, and PK of HPN217 in Patients With R/R MM

Multiple Myeloma | Multiple Myeloma in Relapse | Multiple Myeloma With Failed Remission | Multiple Myeloma of Bone

United States, Spain, France
Intrinsic Therapeutics

Active, not recruiting

Study of Lumbar Discectomy With Annular Closure

Lumbar Disc Herniation

United States
Aligos Therapeutics

Completed

A Study of ALG-055009 in Healthy Volunteers and Subjects With Hyperlipidemia

NASH - Nonalcoholic Steatohepatitis

France
Fate Therapeutics

Terminated

FT538 in Combination With Monoclonal Antibodies in Advanced Solid Tumors

Solid Tumor, Adult

United States
Intellia Therapeutics

Active, not recruiting

Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of NTLA-2001 in Patients With Hereditary Transthyretin Amyloidosis With Polyneuropathy (ATTRv-PN) and Patients With Transthyretin Amyloidosis-Related Cardiomyopathy (ATTR-CM)

Transthyretin-Related (ATTR) Familial Amyloid Cardiomyopathy | Transthyretin-Related (ATTR) Familial Amyloid Polyneuropathy | Wild-Type Transthyretin Cardiac Amyloidosis

France, United Kingdom, New Zealand, Sweden
Allogene Therapeutics

Active, not recruiting

Safety and Efficacy of ALLO-605 an Anti-BCMA Allogeneic CAR T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma

Relapsed/Refractory Multiple Myeloma

United States
Celldex Therapeutics

Completed

A Study of CDX-0159 in Patients With Prurigo Nodularis

Prurigo Nodularis

United States, Germany, Poland
ConSynance Therapeutics

Completed

A Pharmacokinetic and Safety Study of CSTI-500 in Subjects With Prader-Willi Syndrome

Prader-Willi Syndrome

United States
Aprea Therapeutics

Terminated

APR-246 in Combination With Acalabrutinib or Venetoclax Based Therapy in Subjects With R/R Non Hodgkin Lymphomas (NHL) (R/R)

Mantle Cell Lymphoma | Chronic Lymphocytic Leukemia | Non Hodgkin Lymphoma

United States
Amicus Therapeutics

Available

Expanded Access for ATB200/AT2221 for the Treatment of IOPD

Pompe Disease Infantile-Onset

Taiwan, United States, Italy
Amicus Therapeutics

Available

Expanded Access for ATB200/AT2221 for the Treatment of Pompe Disease

Pompe Disease
Celldex Therapeutics

Completed

A Study of CDX-0159 in Patients With Chronic Spontaneous Urticaria

Chronic Spontaneous Urticaria

United States, Germany
Sage Therapeutics

Completed

A Study To Assess The Safe-Use Conditions For Administration of ZULRESSO® in a Home Setting

Postpartum Depression

United States
Fulcrum Therapeutics

Active, not recruiting

Evaluation of Safety, Tolerability, and Changes in Biomarker and Clinical Outcome Assessments of Losmapimod for FSHD1 With Extension (FSHD)

Facioscapulohumeral Muscular Dystrophy 1

Netherlands
Karuna Therapeutics

Terminated

An Open-label Study to Assess the Long-term Safety, Tolerability, Effectiveness, and Durability of Effect of KarXT in Patients With DSM-5 Diagnosis of Schizophrenia (PENNANT)

Schizophrenia

United States
Decibel Therapeutics

Completed

Study to Evaluate Safety and Efficacy of DB-020 to Protect Hearing in Patients Receiving Cisplatin for Cancer Treatment

Ototoxicity

United States, Australia
Fate Therapeutics

Withdrawn

FT596 in Combination With R-CHOP in Subjects With B-Cell Lymphoma

Follicular Lymphoma | Mantle Cell Lymphoma | Marginal Zone Lymphoma | Diffuse Large B Cell Lymphoma | Transformed Indolent Non-Hodgkin's Lymphoma
Tessa Therapeutics

Completed

A Phase III Trial Evaluating Chemotherapy and Immunotherapy for Advanced Nasopharyngeal Carcinoma (NPC) Patients (VANCE)

Nasopharyngeal Carcinoma

United States, Taiwan, Malaysia, Singapore, Thailand
Heron Therapeutics

Completed

Phase 2 Bunionectomy HTX-011 Administration Study

Postoperative Pain

United States
Lava Therapeutics

Active, not recruiting

Trial of LAVA-051 in Patients With Relapsed/Refractory CLL, MM, or AML

Acute Myeloid Leukemia | Multiple Myeloma | Chronic Lymphocytic Leukemia

United States, Spain, France, Netherlands
Mana Therapeutics

Terminated

Study of Mana 312 (Multi Tumor-Associated Antigen T Cells) in Adults With AML/MDS After HSCT

AML/MDS

United States
Corcept Therapeutics

Completed

Retrospective Chart Review Study of Korlym for the Treatment of ACTH Independent Cushing's Syndrome (RE-KLAIM)

Cushing's Syndrome
Windtree Therapeutics

Terminated

A Safety and Efficacy Study of Lucinactant for Inhalation in Preterm Neonates 26 to 32 Weeks Gestational Age

Respiratory Distress Syndrome, Newborn

Poland
Fate Therapeutics

Completed

FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors

Melanoma | Lymphoma | Renal Cell Carcinoma | Cervical Cancer | Head and Neck Cancer | Small Cell Lung Cancer | Hepatocellular Carcinoma | Gastric Cancer | Colorectal Cancer | NSCLC | Advanced Solid Tumors | HER2-positive Breast Cancer | Pancreas Cancer | Urothelial Carcinoma | Merkel Cell Carcinoma | Microsatellite Instability and other conditions

United States
Aligos Therapeutics

Terminated

A Study of ALG-020572 Drug to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics After Single Doses in Healthy Volunteers and Multiple Doses in CHB Subjects

Chronic Hepatitis B

United Kingdom, New Zealand
Prelude Therapeutics

Completed

A Study of PRT811 in Participants With Advanced Solid Tumors, CNS Lymphoma and Gliomas

Advanced Solid Tumor | Recurrent Glioma

United States

Clinical Trials Sponsored by Osiris Therapeutics

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Zambia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations